Streetbeat News

Equity Actions

KULR

KULR Tech Gr's (NYSE:KULR) short interest has significantly increased by 259.44% since the last report, with 12.20 million shares sold short, representing 12.94% of its available trading shares. This high level of short interest, compared to its peer group average of 6.97%, indicates a more bearish market sentiment towards KULR. However, an increase in short interest does not necessarily predict a decline in stock price in the near term.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 3:15 pm

APPN

In the last three months, 5 analysts have updated their ratings on Appian (NASDAQ:APPN), showing a mix of sentiments. The recent evaluations range from bullish to bearish, with a notable shift towards a somewhat bearish stance in the last 30 days. The average 12-month price target for APPN has been adjusted to $44.4, up from $43.80, indicating a slight positive revision in expectations. Analysts' actions, including raising and lowering ratings and price targets, reflect their adaptation to Appian's market performance and recent financial indicators such as revenue growth, net margin, and debt management.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 3:01 pm

MRNA

In the past three months, Moderna (NASDAQ:MRNA) received mixed analyst ratings, ranging from bullish to bearish, with a notable upward trend in the 12-month price targets, now averaging $119.17. Recent analyst actions include ratings and price target adjustments by firms such as Oppenheimer and Jefferies, reflecting changing market dynamics and Moderna's performance. Despite challenges in revenue growth and profitability indicators, Moderna's market presence remains strong, supported by its mRNA technology and a diverse clinical trial pipeline.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 3:00 pm

LLY

A comparative study of Eli Lilly and Co (NYSE:LLY) against its pharmaceutical industry competitors reveals high valuation metrics (PE, PB, PS) suggesting potential overvaluation. Despite lower profitability indicators (ROE, EBITDA, gross profit), Eli Lilly's significant revenue growth outperforms the industry, indicating strong market potential. The analysis includes financial metrics comparison with major competitors, highlighting Eli Lilly's position in terms of valuation, profitability, and growth.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 3:00 pm

PCTY

Paylocity Holding's shares surged following the announcement of Q3 financial results that exceeded expectations. The company also provided optimistic Q4 and FY24 revenue guidance, surpassing estimates. Additionally, a $500 million share repurchase program was approved by the Board of Directors.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 2:25 pm

AAPL

BRK

Warren Buffett's Berkshire Hathaway is set to receive $226M in dividends from Apple following a 4.2% dividend hike. Berkshire's holding in Apple, a core equity, was 904.87 million shares valued at $174.21 billion at the end of Q4. Despite a 10.82% drop in Apple's share value in the March quarter, the dividend income remains significant. Apple's performance has seen fluctuations, with recent revenue declines attributed to China's market. However, prospects may improve with anticipated iPhone sales growth and an 'AI-driven' super-cycle expected with the iPhone 16 release.

Portfolio Pulse from Shanthi Rexaline

May 03, 2024 | 2:23 pm

ARM

ARM Holdings (NASDAQ:ARM) has seen a bearish sentiment from options traders, with 64% of trades being bearish. The trading volume and open interest analysis suggest a targeted price range of $55.0 to $125.0. ARM's stock is currently up by 4.71%, with a price of $102.62. Analyst ratings vary, with an average target price of $108.6, indicating a cautiously optimistic outlook on the stock.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 2:17 pm

CVS

Recent unusual options activity in CVS Health (NYSE:CVS) indicates a predominantly bearish sentiment among big-money traders, with a notable volume of puts over calls. This activity suggests expectations of CVS's stock price moving within a $50.0 to $85.0 range. Despite this bearish outlook, CVS Health's diverse healthcare services and recent acquisitions position it for potential growth. Analyst ratings vary, with a consensus target price of $69.0, reflecting a mix of cautious optimism and neutral stances.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 2:17 pm

ADBE

Adobe (NASDAQ:ADBE) has seen significant options activity, indicating a bullish stance by large investors. Analysis of 9 trades shows a split sentiment, with 33% bullish and 33% bearish. Notable options activity includes both puts and calls, with a focus on strike prices between $460.0 and $500.0. Adobe's stock is currently up by 0.98%, trading at $481.22, with an RSI indicating a neutral position. The next earnings report is expected in 41 days.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 2:17 pm

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo for May 3rd, 2024, provides trading strategies for SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA, based on a proprietary formula. It outlines potential price movements for these assets, suggesting levels for bulls and bears to watch. The memo also highlights the importance of upcoming economic reports, including Non-Farm Payrolls, Average Hourly Earnings, and the ISM Services Index, which could significantly impact market volatility and trading strategies.

Portfolio Pulse from RIPS

May 03, 2024 | 2:12 pm